期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 14, 期 2, 页码 153-162出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0018
关键词
-
类别
资金
- AstraZeneca
- Bayer Healthcare Pharmaceuticals Inc.
- Bristol-Myers Squibb
- Clovis Oncology
- Genentech
- Novartis Oncology
- Otsuka America Pharmaceutical, Inc.
- Seattle Genetics, Inc.
- Takeda Oncology
- Actelion Pharmaceuticals US, Inc.
- Astellas
- Medivation, Inc.
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据